# Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

Study · id `cardio:ct-nct04218266` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04218266](<https://clinicaltrials.gov/study/NCT04218266>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04218266

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.

## Technical summary

Registry record NCT04218266. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-30 (actual); primary completion 2021-10-08 (actual). Results posted on 2022-10-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 755 participants (enrolled count; ClinicalTrials.gov record NCT04218266, source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)
- Started: 2020-01-30 (actual) (ClinicalTrials.gov record NCT04218266, source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)
- Primary completion: 2021-10-08 (actual) (ClinicalTrials.gov record NCT04218266, source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)
- Completion: 2021-10-08 (actual) (ClinicalTrials.gov record NCT04218266, source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)
- Results first posted: 2022-10-27 (ClinicalTrials.gov record NCT04218266, source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)
- Countries: Austria; Belgium; Canada; Czechia; France; Hungary; Italy; Japan; Latvia; Netherlands; Spain; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT04218266, source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04218266-2022-10-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
- Acronym: PACIFIC-AF
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): BAY2433334
- Intervention (Drug): Apixaban
- Intervention (Other): BAY2433334 matching placebo
- Intervention (Other): Apixaban matching placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study (`cardio:pubmed-35385695`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c7ec23bf445dbdc5bd6e399ea13fa22060f74e41e27145a284cc1cbb3d488f9b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
